IL6 and Parkinson disease: Thus, the use of Tocilizumab to prevent IL-6R–related changes in DAn suggests that antibody-mediated blockade/neutralization of IL-6 represents a viable therapeutic strategy to treat PD with a significant translational effect in the design of future therapeutics.